Welcome to our dedicated page for Seer SEC filings (Ticker: SEER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Seer, Inc. (Nasdaq: SEER) SEC filings page provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Seer’s capital structure, governance, and financial reporting practices as a life sciences company focused on deep, unbiased proteomics.
Recent Form 8-K filings include current reports on quarterly financial results, where Seer furnishes press releases describing revenue from Proteograph instruments, consumable kits, and Technology Access Center service projects. Other 8-Ks address corporate governance matters such as the election of directors, ratification of the independent registered public accounting firm, and notices related to Nasdaq listing rule compliance, including audit committee composition.
Seer’s filings also document important changes to its equity structure. A December 2025 Form 8-K describes the automatic conversion of all outstanding Class B common stock into Class A common stock pursuant to the company’s Amended and Restated Certificate of Incorporation, the subsequent retirement of the Class B shares, and the filing of a Certificate of Retirement in Delaware. The filing explains how this conversion affected voting power while leaving economic interests unchanged, and confirms that Seer’s Class A common stock continues to trade on The Nasdaq Global Select Market under the SEER ticker.
On Stock Titan, Seer’s SEC filings are updated as they are made available through EDGAR, and AI-powered summaries can help explain the key points of complex documents. Users can quickly identify items related to financial results, stock structure changes, governance decisions, and listing status, and then drill into the full filings for deeper review. This makes it easier to understand how Seer reports on its Proteograph-focused business and its obligations as a Nasdaq-listed issuer.